Berson & Corrado Investment Advisors LLC grew its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,442 shares of the biopharmaceutical company’s stock after purchasing an additional 55 shares during the period. Berson & Corrado Investment Advisors LLC’s holdings in Pfizer were worth $1,291,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Asset Planning Services Ltd. lifted its stake in Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. Orrstown Financial Services Inc. lifted its stake in Pfizer by 23.0% during the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer during the first quarter worth $121,000. Patten Group Inc. lifted its stake in Pfizer by 5.1% during the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 252 shares in the last quarter. Finally, Kimelman & Baird LLC acquired a new position in Pfizer during the first quarter worth $203,000. Institutional investors own 69.00% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) traded up 0.42% during trading on Thursday, hitting $36.14. The company’s stock had a trading volume of 5,279,640 shares. The firm’s 50 day moving average price is $33.78 and its 200-day moving average price is $33.53. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.19. The company has a market cap of $214.94 billion, a PE ratio of 26.44 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 EPS. On average, analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Berson & Corrado Investment Advisors LLC Grows Holdings in Pfizer, Inc. (PFE)” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/berson-corrado-investment-advisors-llc-grows-holdings-in-pfizer-inc-pfe/1578503.html.

A number of research firms have recently weighed in on PFE. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Berenberg Bank set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, August 1st. Morgan Stanley reaffirmed a “neutral” rating and set a $35.00 price objective (down previously from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a research report on Wednesday, September 13th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $38.04.

In other news, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 in the last three months. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.